A 62-year-old woman from Mumbai with a BMI of 38 kg/m² presents with abnormal uterine bleeding and pelvic pain for 4 months. She has a history of unopposed estrogen exposure (no prior hysterectomy, never used hormonal contraception). Transvaginal ultrasound reveals an endometrial thickness of 22 mm with a heterogeneous mass. Endometrial biopsy shows grade 3 endometrioid adenocarcinoma with >50% myometrial invasion. MRI pelvis confirms myometrial invasion and a 3 cm mass. Staging CT chest and abdomen shows no distant metastases, but pelvic lymph nodes are not enlarged on imaging. She has no contraindications to surgery. What is the most appropriate management strategy?

Explanation

## Management of Intermediate-to-High-Risk Endometrial Cancer **Key Point:** Grade 3 endometrial cancer with deep myometrial invasion (>50%) is classified as stage IB–II and carries significant risk of lymph node and distant metastases. Comprehensive surgical staging followed by adjuvant multimodal therapy is the standard of care. ### Risk Stratification This patient has **multiple high-risk features:** | Risk Factor | Present | Significance | |------------|---------|-------------| | **Grade 3 histology** | Yes | Highest grade; poor differentiation | | **Myometrial invasion >50%** | Yes | Stage IB; increases risk of nodal/distant spread | | **Endometrioid type** | Yes | More common; still aggressive at grade 3 | | **Obesity + unopposed estrogen** | Yes | Chronic estrogen exposure increases risk | | **Tumor size 3 cm** | Yes | Larger tumors have higher metastatic potential | **High-Yield:** Grade 3 with myometrial invasion >50% = **stage IB endometrial cancer**. Risk of pelvic/para-aortic nodal involvement is 15–20% even with negative imaging; surgical staging is mandatory. ### Surgical Staging Approach **Mnemonic: COMPREHENSIVE STAGING — LYMPH:** - **L**ymph node dissection (pelvic AND para-aortic) — essential for stage IB - **Y**sterectomy (total abdominal preferred over vaginal for better access) - **M**yometrial assessment (depth of invasion confirmed) - **P**eritoneal cytology (if available) - **H**ysterectomy with BSO (bilateral salpingo-oophorectomy) **Clinical Pearl:** Abdominal hysterectomy (not vaginal) is preferred in high-risk disease because it allows better assessment of the tumor, easier access for lymph node dissection, and evaluation of peritoneal surfaces. ### Adjuvant Therapy After Surgery Once final pathology and lymph node status are known: **If nodes are negative (likely in this case):** - Adjuvant chemotherapy (carboplatin + paclitaxel × 6 cycles) ± vaginal brachytherapy - Chemotherapy reduces recurrence risk in grade 3 with myoinvasion **If nodes are positive:** - Chemotherapy + pelvic/para-aortic external beam radiation therapy (EBRT) **If stage III (nodal involvement confirmed):** - Multimodal: surgery + chemotherapy + radiation ```mermaid flowchart TD A[Grade 3 endometrial cancer<br/>with myometrial invasion >50%]:::outcome --> B[Surgical staging:<br/>TAH-BSO + pelvic & para-aortic<br/>lymph node dissection]:::action B --> C{Lymph node<br/>status?}:::decision C -->|Negative| D[Adjuvant chemotherapy<br/>± vaginal brachytherapy]:::action C -->|Positive| E[Chemotherapy + EBRT<br/>+ brachytherapy]:::action D --> F[Follow-up surveillance]:::outcome E --> F ``` **Warning:** Imaging alone (CT/MRI) has limited sensitivity for detecting microscopic nodal disease; imaging-negative does NOT exclude nodal metastases. Surgical dissection is necessary for accurate staging. [cite:NCCN Endometrial Cancer Guidelines 2023; Robbins 10e Ch 24]